1. Market Research
  2. > Pharmaceutical
  3. > Drug Delivery Market Trends

Global Transdermal Drug Delivery Partnering 2010-2017: Deal trends, players, financials and forecasts

  • March 2017
  • 160 pages
  • Currentpartnering
Report ID: 3754619

Summary

Table of Contents

Summary
Global Transdermal Drug Delivery Partnering 2010-2017 provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies

Description
Transdermal Drug Delivery Partnering 2010-2017 report provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.

Trends in transdermal drug delivery partnering deals
Top transdermal drug delivery deals by value
Deals listed by company A-Z, deal type, stage of development, therapy type

This report provides details of the latest Transdermal Drug Delivery agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Transdermal Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Transdermal Drug Delivery partnering deals.

The report presents financial deal term values for Transdermal Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Transdermal Drug Delivery partnering field; both the leading deal values and most active Transdermal Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 150 online deal records of actual Transdermal Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Transdermal Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Transdermal Drug Delivery dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Transdermal Drug Delivery deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Transdermal Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Transdermal Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Transdermal Drug Delivery partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Transdermal Drug Delivery partnering deals signed and announced since Jan 2010. The chapter is organized by specific Transdermal Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Transdermal Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Transdermal Drug Delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Transdermal Drug Delivery technologies and products.

Key benefits

Global Transdermal Drug Delivery Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:
- In-depth understanding of Transdermal Drug Delivery deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Transdermal Drug Delivery agreements with numerous real life case studies
- Detailed access to actual Transdermal Drug Delivery contracts entered into by leading biopharma companies
- Identify most active Transdermal Drug Delivery dealmakers since 2010
- Insight into terms included in a Transdermal Drug Delivery partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope
Global Transdermal Drug Delivery Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Transdermal Drug Delivery trends and structure of deals entered into by leading companies worldwide.

Transdermal Drug Delivery Partnering Terms and Agreements includes:
- Trends in Transdermal Drug Delivery dealmaking in the biopharma industry since 2010
- Analysis of Transdermal Drug Delivery deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Transdermal Drug Delivery deals
- Access to Transdermal Drug Delivery contract documents
- Leading Transdermal Drug Delivery deals by value since 2010
- Most active Transdermal Drug Delivery dealmakers since 2010

In Global Transdermal Drug Delivery Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Transdermal Drug Delivery Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 150 Transdermal Drug Delivery deals.

Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Transdermal Drug Delivery Partnering 2010-2017 provides the reader with the following key benefits:
- In-depth understanding of Transdermal Drug Delivery deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Transdermal Drug Delivery agreements with numerous real life case studies
- Detailed access to actual Transdermal Drug Delivery contracts entered into by leading biopharma companies
- Identify most active Transdermal Drug Delivery dealmakers since 2010
- Insight into terms included in a Transdermal Drug Delivery partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
Global Transdermal Drug Delivery System Market Analysis 2016 - Forecast to 2022

Global Transdermal Drug Delivery System Market Analysis 2016 - Forecast to 2022

  • $ 4550
  • Industry report
  • February 2017
  • by Hoovers Research

Hoovers Research analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present ...

Drug Delivery System Markets in China

Drug Delivery System Markets in China

  • $ 4000
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

China’s demand for Drug Delivery System has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...

Vaccine Delivery Markets for Microneedle Devices

Vaccine Delivery Markets for Microneedle Devices

  • $ 3850
  • Industry report
  • February 2017
  • by Greystone Research Associates

Vaccine Delivery Markets for Microneedle Devices - Technology, Markets, Players, Strategies and Forecasts Vaccines are recognized as one of the most significant healthcare developments in the last one ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.